Neumora Therapeutics, Inc. (NMRA) - Total Assets
Based on the latest financial reports, Neumora Therapeutics, Inc. (NMRA) holds total assets worth $177.83 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neumora Therapeutics, Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Neumora Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see Neumora Therapeutics, Inc. (NMRA) market capitalisation for the company's overall valuation and market capitalisation.
Neumora Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Neumora Therapeutics, Inc.'s total assets of $177.83 Million consist of 99.1% current assets and 0.9% non-current assets. Review debt load of Neumora Therapeutics, Inc. to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Neumora Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Neumora Therapeutics, Inc. (NMRA) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neumora Therapeutics, Inc.'s current assets represent 99.1% of total assets in 2024, an increase from 0.0% in 2019.
- Cash Position: Cash and equivalents constituted 44.9% of total assets in 2024, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Neumora Therapeutics, Inc. Competitors by Total Assets
Key competitors of Neumora Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Neumora Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.85 | 10.98 | 20.69 |
| Quick Ratio | 6.85 | 10.98 | 20.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $151.24 Million | $316.87 Million | $184.47 Million |
Neumora Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Neumora Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.11 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | -36.1% |
| Total Assets | $316.97 Million |
| Market Capitalization | $127.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Neumora Therapeutics, Inc.'s assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Neumora Therapeutics, Inc.'s assets decreased by 36.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neumora Therapeutics, Inc. (2019–2024)
The table below shows the annual total assets of Neumora Therapeutics, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $316.97 Million | -36.12% |
| 2023-12-31 | $496.19 Million | +16.41% |
| 2022-12-31 | $426.23 Million | -0.71% |
| 2021-12-31 | $429.30 Million | +116.88% |
| 2020-12-31 | $197.95 Million | -- |
| 2019-12-31 | $0.00 | -- |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more